Document mp6n2ajyd4X6VekyobGjLBpjg

Benzene Health Research Consortium Technical Committee Dra.ft Minutes Conference Call - 18 Nov 2004 Participants Patrick Beatty (ChevronTexaco) Steve Bose (ExxonMobil) Don Burnett (BP) Stuart Cagen (Shell) Jennifer Galvin (ConocoPhillips) Howard Feldman (API; part-time) Bruce Jarnot (API) Administrative Items Call was conducted in accordance with API antitrust guidelines Agenda: discuss I review "action items" generated at early-November OC meeting in Houston o Expectation to provide update(s) by 10 December 2004 Background Most Action Items can likely be met by PI discussion(s) $3.3MM gap identified by Pis has led to sense of urgency o OC deferred most action items to the TC o Funding required to carry the studies to completion o Approx 2x of Rich Irons Oct 2004 estimate o Possible BP $1.?MM added contribution? o May not include Richard's T&E increase, post-200? General Discussion Items ActiOn - Prioritization under current funding? (Alternate approach, still pending ...) o Prioritization by SRP/ERP o Prioritization by Pis? o Consequences & implications noted if studies re-scoped by prioritization Draft Minutes for Review Page 1of3 SHELL-MCCLURG-057018 Benzene Health Research Consortium Technical Committee Meeting Notes o OC has ID'ed -$600K possible cost savings ("sweat equity" approach) Added cost of exposu re assessment o How much of Yimei's costs embedded in Richard's re-analysis? 2-month (longer?) replacement for Patrick not ID'ed (ChevronTexaco) o Patrick will be on short term disability starting end-of-December _ : Discuss "Action Items" in-person with Richard o Benefit seen of having Denver meeting with Richard & -TC o Invite Otto to attend/participate? o ActloA: Patrick/Stuart to call or email regarding possible meeting Long-standing Action Items .icH8H: Review Munich attendee list for possible scientific involvement follow-up o Defer to 2005, pending resolution of scope scale-back & budget reanalysis o Might this miss a window of opportunity (risk of becoming a "stale issue"?) ActiOn: Do we need a formal QA/QC audit of Shanghai? o _ : affirm recommendation that this -$1 OOK line-item be dropped o QA/QC will be internally covered by JCML lab accreditation o _ : TC delegation to visit & "spot check" lab operations Goes toward demonstrating sponsor due diligence New Action Items Nat Rothman (NCI Investigator) proposed NCI/Consortium collaboration o NCI China CC Study proposed, beginning 2007 mctlon:o TC to discuss NCI's offer with PI's o _ : include in PI discussions .idti8H: options for JCML continuation, via outside funding? o Contingent upon Fudan plans ... Draft Minutes for Review Page 2 of3 SHELL-MCCLURG-057019 Benzene Health Research Consortium Technical Committee Meeting Notes o Continue within School of Public Health (i.e., likely to be shut down) o Or establish JCML as separate, free-standing department o Fudan decision possible by end-of-year o _ : Ask Richard if he sees value in having Company rep's meeting with Fudan (risk of sponsors "taking sides" with internal Fudan politics?) o _ : include in PI discussions IctiOn: confirm Budget Re-analyses as being complete & comprehensive o Anything overlooked (e.g., Richard T&E cost increase) o Any "cost overlap" (e.g., Yimei's time-in-field in Richard's re-analysis vs. EMBSI funding her effort) o _ : include in PI discussions ActiOn: reality check of exposure assessment o Do we need more than a yes/no for CC exposures? o Is there an association between Bz and NHL? AML? o CC dose-response may be "nice to have", but not critical to study o _ : check w/ SRP & Pis ... can we cut back on level of assessment? don't need to hit a home run each time to win the game o _ : include in PI discussion 1. Pis to reconsider "what can really be done" in exposure assessment?" 2. Will this provide some of the answers (may be an ethics consideration) Draft Minutes for Review Page 30f3 SH ELL-MCCLU RG-057020